INVESTOR ALERT: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – IMMU
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that a class action lawsuit has been filed against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) on behalf of investors who purchased the Company’s common stock between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”).
Investors who purchased the Company’s common stock during the Class Period and suffered a financial loss in excess of $100,000 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740 to discuss their legal rights and options. Additional information about this action may also be found at http://kaskelalaw.com/case/immunomedics-inc/.
The class action complaint alleges that Immunomedics misled investors during the Class Period by stating in its SEC filings that “the FDA generally will issue a notice on Form 483 if it finds issues with respect to its inspections” without disclosing to investors the fact that, between August 6, 2018, and August 14, 2018, the FDA cited Immunomedics for a host of violations observed at its Morris Plains, New Jersey, drug substance manufacturing facility. These violations included manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.
On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” According to the article, “[t]he FDA cited Immunomedics for a host of violations - including its handling of a data integrity breach - observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article reported that the breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.” Following this report, shares of Immunomedics’ stock declined to $17.86 per share.
Subsequently, on December 20, 2018, Favus Institutional Research issued a report (the “Favus Report”) further detailing the data integrity breach. Following the Favus Report, shares of the Company’s stock declined $3.47 per share, or nearly 20% in value, to close on December 20, 2018 at $14.17 per share, on heavy trading volume.
IMPORTANT DEADLINE: Investors who purchased Immunomedics’s common stock during the Class Period may, no later than February 25, 2019, seek to be appointed as a lead plaintiff representative of the class.
Investors who purchased the Company’s common stock during the Class Period and suffered a financial loss in excess of $100,000 are encouraged to contact Kaskela Law LLC for additional information about this action and their legal rights and options. Kaskela Law LLC exclusively represents investors in state and federal courts throughout the country. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.